Control of Mycoflora Associated with Pigeonpea Seeds

Associated with the seeds of four field-grown pigeonpea cultivars, Alternaria sp., Aspergillus flavus, A. niger, Fusarium spp., and Rhizoctonia bataticola were predominant. Cultivars NP-69 (late) and Prabhat (extra early) harbored more fungi than did T-21 (early) or ICP-1 (mid). Genotypic differences rather than weather during pod maturity, or different storage periods seem to Influence the intensity or seed-borne mycoflora. Greater reduction in seed germination was observed incultivars NP-69 and Prabhat which had higher frequency of mycoflora, especially Aspergillus spp. Seed treatment with Benlate T at 3 g/kg provided crmplete control of all seed-borne fungi with no adverse effect on germination. This treatment can be recommended for controlling seed-borne mycoflora to ensure safe imernational exchange of seed

Prevalence of Pigeonpea Wilt and Sterility Mosaic in India(1975-80)

In the 11 states surveyed incidence of Fusarium udum varied from 0.1% in Rajasthan to 22.6% in Maharashtra, and of pigeon pea sterility mosaic virus from 0.2% in West Bengal to 21.4% in Biha

Prevalence of pigeonpea diseases and associated crop losses in Asia, Africa and the Americas.

Surveys were carried out to determine the prevalence of pigeonpea diseases in the major pigeonpea growing areas of Asia, Africa and the Americas between 1975 and 1980. In India, surveys in eleven states revealed that wilt, sterility mosaic, Phytophthora blight, Macrophomina stem canker and yellow mosaic were economically important diseases. Other diseases were of minor importance. Disease problems in Bangladesh, Malaysia and Nepal were of less importance. In Africa, wilt was a serious disease in Malawi (36.3%), Tanzania (20.4%) and Kenya (15.9%). Leaf spot in Kenya and Malawi, and powdery mildew in Kenya, Tanzania and Zambia were important. Other diseases were not economically important. In the Americas witches' broom, Phoma stem canker and rust were the important diseases. Annual crop losses due to the combined effect of wilt and sterility mosaic diseases in India were estimated to be worth about US$113 millions. In Africa the estimated losses from wilt disease alone were over US$ 5 millions annually

Expression of Lineage Transcription Factors Identifies Differences in Transition States of Induced Human Oligodendrocyte Differentiation

Oligodendrocytes (OLs) are critical for myelination and are implicated in several brain disorders. Directed differentiation of human-induced OLs (iOLs) from pluripotent stem cells can be achieved by forced expression of different combinations of the transcription factors SOX10 (S), OLIG2 (O), and NKX6.2 (N). Here, we applied quantitative image analysis and single-cell transcriptomics to compare different transcription factor (TF) combinations for their efficacy towards robust OL lineage conversion. Compared with S alone, the combination of SON increases the number of iOLs and generates iOLs with a more complex morphology and higher expression levels of myelin-marker genes. RNA velocity analysis of individual cells reveals that S generates a population of oligodendrocyte-precursor cells (OPCs) that appear to be more immature than those generated by SON and to display distinct molecular properties. Our work highlights that TFs for generating iOPCs or iOLs should be chosen depending on the intended application or research question, and that SON might be beneficial to study more mature iOLs while S might be better suited to investigate iOPC biology

Intercropping studies with annual crops

This paper tries to illustrate how beneficial interactions between crops can be exploited to increase the overall output of a cropping system. Growth studies with sorghum/pigeonpea and millet/groundnut are described to show how intercropping systems can achieve much larger yields than sole crops by using environmental resources more fully over time or more efficiently in space. Data from moisture stress studies are presented to illustrate that these advantages of intercropping can be even greater under stress conditions. Possible nitrogen benefits from legumes in intercropping systems are discussed with particular reference to a study on maize/groundnut. Weed, pest and disease control are considered and some effects of a sorghum intercrop on the incidence of pod borer and wilt disease in pigeonpea are described. Evidence for improved yield stability in intercropping systems is provided from a review of 94 experiments on sorghum/pigeonpea. It is emphasized that intercropping is especially beneficial to the small farmer in the low-input/high-risk environment of the developing areas of the world but some brief comments are made on its applicability in more developed conditions

Studies on inheritance of resistance and allelic relationships for strain 2 of pigeonpea sterility mosaic pathogen

Inheritance of resistance and allelic relationships were studied in three resistant pigeonpea sources for strain 2 of sterility mosaic pathogen. The resistant genotypes (ICP 7035, ICP 7349 and ICP 8850) were crossed with susceptible genotypes (BDN1 and LRG30) to determine the inheritance of resistance. The resistant and susceptible genotypes were also crossed among themselves to obtain information on their allelic relationships. Parents, F1 and F2 generations were sown in pots and screened using infector-hedge technique. Observations in parents, F1 and F2 generations, indicated dominance of resistance in certain crosses and the dominance of susceptibility in others. Disease reaction appeared to be governed by two independent non-allelic genes, with at least three multiple alleles, at one of the loc

Negative regulation of signal transducer and activator of transcription-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cells

Background: Constitutive activation of signal transducer and activator of transcription signalling 3 (STAT3) has been linked with survival, proliferation and angiogenesis in a wide variety of malignancies including hepatocellular carcinoma (HCC). Methods: We evaluated the effect of lupeol on STAT3 signalling cascade and its regulated functional responses in HCC cells. Results: Lupeol suppressed constitutive activation of STAT3 phosphorylation at tyrosine 705 residue effectively in a dose- and time-dependent manner. The phosphorylation of Janus-activated kinases (JAKs) 1 and 2 and Src was also suppressed by lupeol. Pervanadate treatment reversed the downregulation of phospho-STAT3 induced by lupeol, thereby indicating the involvement of a phosphatase. Indeed, we observed that treatment with lupeol increased the protein and mRNA levels of SHP-2, and silencing of SHP-2 abolished the inhibitory effects of lupeol on STAT3 activation. Treatment with lupeol also downregulated the expression of diverse STAT3-regulated genes and decreased the binding of STAT3 to VEGF promoter. Moreover, the proliferation of various HCC cells was significantly suppressed by lupeol, being associated with substantial induction of apoptosis. Depletion of SHP-2 reversed the observed antiproliferative and pro-apoptotic effects of lupeol. Conclusions: Lupeol exhibited its potential anticancer effects in HCC through the downregulation of STAT3-induced pro-survival signalling cascade

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie